Slingshot members are tracking this event:

Interim Phase 1b/2 Results for Merck's (MRK) Keytruda and Eisai's (ESALY) Halaven in Triple-Negative Breast Cancer (TNBC) Presented at the San Antonio Breast Cancer Symposium

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 12, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1b/2, Interim Results, Keytruda, Halaven, Metastatic Triple-negative Breast Cancer, Tnbc, San Antonio Breast Cancer Symposium